|
2021 Journal Article Short duration alagebrium chloride therapy prediabetes does not inhibit progression to autoimmune diabetes in an experimental modelBorg, Danielle J., Faridi, Pouya, Giam, Kai Lin, Reeves, Peta, Fotheringham, Amelia K., McCarthy, Domenica A., Leung, Sherman, Ward, Micheal S., Harcourt, Brooke E., Ayala, Rochelle, Scheijen, Jean L., Briskey, David, Dudek, Nadine L., Schalkwijk, Casper G., Steptoe, Raymond, Purcell, Anthony W. and Forbes, Josephine M. (2021). Short duration alagebrium chloride therapy prediabetes does not inhibit progression to autoimmune diabetes in an experimental model. Metabolites, 11 (7) 426, 1-21. doi: 10.3390/metabo11070426 |
|
2021 Journal Article Advanced glycation end products as predictors of renal function in youth with type 1 diabetesForbes, Josephine M., Le Bagge, Selena, Righi, Samuel, Fotheringham, Amelia K., Gallo, Linda A., McCarthy, Domenica A., Leung, Sherman, Baskerville, Tracey, Nisbett, Janelle, Morton, Adam, Teasdale, Stephanie, D'Silva, Neisha, Barrett, Helen, Jones, Timothy, Couper, Jennifer, Donaghue, Kim, Isbel, Nicole, Johnson, David W., Donnellan, Leigh, Deo, Permal, Akison, Lisa K., Moritz, Karen M. and O'Moore-Sullivan, Trisha (2021). Advanced glycation end products as predictors of renal function in youth with type 1 diabetes. Scientific Reports, 11 (1) 9422, 9422. doi: 10.1038/s41598-021-88786-4 |
|
2021 Journal Article Long term high protein diet feeding alters the microbiome and increases intestinal permeability, systemic inflammation and kidney injury in miceSnelson, Matthew, Clarke, Rachel Elise, Nguyen, Tuong-Vi, Penfold, Sally Anne, Forbes, Josephine Maree, Tan, Sih Min and Coughlan, Melinda Therese (2021). Long term high protein diet feeding alters the microbiome and increases intestinal permeability, systemic inflammation and kidney injury in mice. Molecular Nutrition and Food Research, 65 (8) 2000851, 1-12. doi: 10.1002/mnfr.202000851 |
|
2021 Journal Article Processed foods drive intestinal barrier permeability and microvascular diseasesSnelson, Matthew, Tan, Sih Min, Clarke, Rachel E., De Pasquale, Cassandra, Thallas-Bonke, Vicki, Nguyen, Tuong-Vi, Penfold, Sally A., Harcourt, Brooke E., Sourris, Karly C., Lindblom, Runa S., Ziemann, Mark, Steer, David, El-Osta, Assam, Davies, Michael J., Donnellan, Leigh, Deo, Permal, Kellow, Nicole J., Cooper, Mark E., Woodruff, Trent M., Mackay, Charles R., Forbes, Josephine M. and Coughlan, Melinda T. (2021). Processed foods drive intestinal barrier permeability and microvascular diseases. Science Advances, 7 (14) eabe4841, 1-16. doi: 10.1126/sciadv.abe4841 |
|
2021 Journal Article Impact of dietary carbohydrate type and protein–carbohydrate interaction on metabolic healthWali, Jibran A., Milner, Annabelle J., Luk, Alison W. S., Pulpitel, Tamara J., Dodgson, Tim, Facey, Harrison J. W., Wahl, Devin, Kebede, Melkam A., Senior, Alistair M., Sullivan, Mitchell A., Brandon, Amanda E., Yau, Belinda, Lockwood, Glen P., Koay, Yen Chin, Ribeiro, Rosilene, Solon-Biet, Samantha M., Bell-Anderson, Kim S., O’Sullivan, John F., Macia, Laurence, Forbes, Josephine M., Cooney, Gregory J., Cogger, Victoria C., Holmes, Andrew, Raubenheimer, David, Le Couteur, David G. and Simpson, Stephen J. (2021). Impact of dietary carbohydrate type and protein–carbohydrate interaction on metabolic health. Nature Metabolism, 3 (6), 810-828. doi: 10.1038/s42255-021-00393-9 |
|
2021 Journal Article The AGE receptor, OST48 drives podocyte foot process effacement and basement membrane expansion (alters structural composition)Zhuang, Aowen, Yap, Felicia Y. T., Borg, Danielle J., McCarthy, Domenica, Fotheringham, Amelia, Leung, Sherman, Penfold, Sally A., Sourris, Karly C., Coughlan, Melinda T., Schulz, Benjamin L. and Forbes, Josephine M. (2021). The AGE receptor, OST48 drives podocyte foot process effacement and basement membrane expansion (alters structural composition). Endocrinology, Diabetes and Metabolism, 4 (3) e00278, e00278. doi: 10.1002/edm2.278 |
|
2020 Journal Article Going in early: hypoxia as a target for kidney disease prevention in diabetes?Barrett, Helen L., Donaghue, Kim C. and Forbes, Josephine M. (2020). Going in early: hypoxia as a target for kidney disease prevention in diabetes?. Diabetes, 69 (12), 2578-2580. doi: 10.2337/dbi20-0037 |
|
2020 Journal Article Circulating levels of the soluble receptor for AGE (sRAGE) during escalating oral glucose dosages and corresponding isoglycaemic i.v. glucose infusions in individuals with and without type 2 diabetesFotheringham, Amelia K., Bagger, Jonatan I., Borg, Danielle J., McCarthy, Domenica A., Holst, Jens J., Vilsbøll, Tina, Knop, Filip K. and Forbes, Josephine M. (2020). Circulating levels of the soluble receptor for AGE (sRAGE) during escalating oral glucose dosages and corresponding isoglycaemic i.v. glucose infusions in individuals with and without type 2 diabetes. Nutrients, 12 (10) 2928, 2928-12. doi: 10.3390/nu12102928 |
|
2020 Journal Article Transient intermittent hyperglycemia accelerates atherosclerosis by promoting myelopoiesisFlynn, Michelle C., Kraakman, Michael J., Tikellis, Christos, Lee, Man Ks, Hanssen, Nordin Mj, Kammoun, Helene L., Pickering, Raelene, Dragoljevic, Dragana, Al-Sharea, Annas, Barrett, Tessa J., Hortle, Fiona, Byrne, Frances L., Olzomer, Ellen, McCarthy, Domenica A., Schalkwijk, Casper G., Forbes, Josephine M., Hoehn, Kyle, Makowski, Liza, Lancaster, Graeme I., El-Osta, Assam, Fisher, Edward A., Goldberg, Ira J., Cooper, Mark E., Nagareddy, Prabhakara R., Thomas, Merlin C. and Murphy, Andrew J. (2020). Transient intermittent hyperglycemia accelerates atherosclerosis by promoting myelopoiesis. Circulation Research, 127 (7) CIRCRESAHA.120.316653, 877-892. doi: 10.1161/CIRCRESAHA.120.316653 |
|
2020 Journal Article Prolyl hydroxylase inhibitors: a breath of fresh air for diabetic kidney disease?Forbes, Josephine M. (2020). Prolyl hydroxylase inhibitors: a breath of fresh air for diabetic kidney disease?. Kidney International, 97 (5), 855-857. doi: 10.1016/j.kint.2020.01.038 |
|
2020 Journal Article Disruption of glycogen utilization markedly improves the efficacy of carboplatin against preclinical models of clear cell ovarian carcinomaKhan, Tashbib, He, Yaowu, Kryza, Thomas, Harrington, Brittney S., Gunter, Jennifer H., Sullivan, Mitchell A., Cuda, Tahleesa, Rogers, Rebecca, Davies, Claire M., Broomfield, Amy, Gough, Madeline, Wu, Andy C., McGann, Thomas, Weroha, S. John, Haluska, Paul, Forbes, Josephine M., Armes, Jane E., Barry, Sinead C., Coward, Jermaine I., Jagasia, Nisha, Chetty, Naven, Snell, Cameron E., Lourie, Rohan, Perrin, Lewis C. and Hooper, John D. (2020). Disruption of glycogen utilization markedly improves the efficacy of carboplatin against preclinical models of clear cell ovarian carcinoma. Cancers, 12 (4) 869, 869. doi: 10.3390/cancers12040869 |
|
2020 Journal Article Targeting the receptor for advanced glycation end products (RAGE) in type 1 diabetesLe Bagge, Selena, Fotheringham, Amelia K., Leung, Sherman S. and Forbes, Josephine M. (2020). Targeting the receptor for advanced glycation end products (RAGE) in type 1 diabetes. Medicinal Research Reviews, 40 (4) med.21654, 1200-1219. doi: 10.1002/med.21654 |
|
2020 Journal Article Delineating a role for the mitochondrial permeability transition pore in diabetic kidney disease by targeting cyclophilin DLindblom, Runa S. J., Higgins, Gavin C., Nguyen, Tuong-Vi, Arnstein, Maryann, Henstridge, Darren C., Granata, Cesare, Snelson, Matthew, Thallas-Bonke, Vicki, Cooper, Mark E., Forbes, Josephine M. and Coughlan, Melinda T. (2020). Delineating a role for the mitochondrial permeability transition pore in diabetic kidney disease by targeting cyclophilin D. Clinical Science, 134 (2), 239-259. doi: 10.1042/CS20190787 |
|
2019 Journal Article Complement C5a induces renal injury in diabetic kidney disease by disrupting mitochondrial metabolic agilityTan, Sih Min, Ziemann, Mark, Thallas-Bonke, Vicki, Snelson, Matthew, Kumar, Vinod, Laskowski, Adrienne, Nguyen, Tuong-Vi, Huynh, Kevin, Clarke, Michele V., Libianto, Renata, Baker, Scott T., Skene, Alison, Power, David A., MacIsaac, Richard J., Henstridge, Darren C., Wetsel, Rick A., El-Osta, Assam, Meikle, Peter J., Wilson, Scott G., Forbes, Josephine M., Cooper, Mark E., Ekinci, Elif I., Woodruff, Trent M. and Coughlan, Melinda T. (2019). Complement C5a induces renal injury in diabetic kidney disease by disrupting mitochondrial metabolic agility. Diabetes, 69 (1), 83-98. doi: 10.2337/db19-0043 |
|
2019 Journal Article Development and progression of non-alcoholic fatty liver disease: the role of advanced glycation end productsFernando, Dinali H., Forbes, Josephine M., Angus, Peter W. and Herath, Chandana B. (2019). Development and progression of non-alcoholic fatty liver disease: the role of advanced glycation end products. International Journal of Molecular Sciences, 20 (20) 5037, 5037. doi: 10.3390/ijms20205037 |
|
2019 Journal Article Genetic characterization of early renal changes in a novel mouse model of diabetic kidney diseaseBalmer, Lois A., Whiting, Rhiannon, Rudnicka, Caroline, Gallo, Linda A., Jandeleit, Karin A., Chow, Yan, Chow, Z., Richardson, Kirsty L., Forbes, Josephine M. and Morahan, G. (2019). Genetic characterization of early renal changes in a novel mouse model of diabetic kidney disease. Kidney International, 96 (4), 918-926. doi: 10.1016/j.kint.2019.04.031 |
|
2019 Journal Article Globally elevating the AGE clearance receptor, OST48, does not protect against the development of diabetic kidney disease, despite improving insulin secretionZhuang, Aowen, Yap, Felicia Y. T., McCarthy, Domenica, Leung, Chris, Sourris, Karly C., Penfold, Sally A., Thallas-Bonke, Vicki, Coughlan, Melinda T., Schulz, Benjamin L. and Forbes, Josephine M. (2019). Globally elevating the AGE clearance receptor, OST48, does not protect against the development of diabetic kidney disease, despite improving insulin secretion. Scientific Reports, 9 (1) 13664, 13664. doi: 10.1038/s41598-019-50221-0 |
|
2019 Journal Article Glucose and glycogen in the diabetic kidney: heroes or villains?Sullivan, Mitchell A. and Forbes, Josephine M. (2019). Glucose and glycogen in the diabetic kidney: heroes or villains?. EBioMedicine, 47, 590-597. doi: 10.1016/j.ebiom.2019.07.067 |
|
2019 Journal Article Response to Letter to the Editor: "Advanced Glycation End Products and esRAGE Are Associated With Bone Turnover and Incidence of Hip Fracture in Older Men"Lamb, Lydia S., Davis, Timothy M E, Forbes, Josephine, Irrgang, Felix, Golledge, Jonathan, Flicker, Leon and Yeap, Bu B. (2019). Response to Letter to the Editor: "Advanced Glycation End Products and esRAGE Are Associated With Bone Turnover and Incidence of Hip Fracture in Older Men". Journal of Clinical Endocrinology and Metabolism, 104 (3), 684-685. doi: 10.1210/jc.2018-02198 |
|
2019 Journal Article The effect of a low carbohydrate formula on glycaemia in critically ill enterally-fed adult patients with hyperglycaemia: a blinded randomised feasibility trialDoola, Ra'eesa, Deane, Adam M., Tolcher, Debbie M., Presneill, Jeffrey J., Barrett, Helen L., Forbes, Josephine M., Todd, Alwyn S., Okano, Satomi and Sturgess, David J. (2019). The effect of a low carbohydrate formula on glycaemia in critically ill enterally-fed adult patients with hyperglycaemia: a blinded randomised feasibility trial. Clinical Nutrition ESPEN, 31, 80-87. doi: 10.1016/j.clnesp.2019.02.013 |
